Systemic Chemo-Immunotherapy for Hepatocellular Carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

刘允怡 ¹ , 赖俊雄 ¹ , 梁惠棠 ²

Corresponding author：

Keywords：

肝癌; 全身免疫化疗; 免疫治疗; 化疗; 手术切除

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 刘允怡,赖俊雄,梁惠棠. Systemic Chemo-Immunotherapy for Hepatocellular Carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2006, 13(2): 129-131. doi: Copy

1.	[J]. Surgeon， 2005； 3（3）∶210.
2.	[J]. Ann Surg， 2001； 233（2）∶236.
3.	[J]. ChineseGerman J Clin Oncol， 2004； 3（3）∶130.
4.	[J]. J R Soc Med, 1985； 78（10）∶826.
5.	[J]. Cancer， 1990； 66（1）∶135.
6.	[J]. Eur J Cancer, 1990； 26（4）∶545.
7.	[J]. Hepatology, 2000； 31（1）∶54.
8.	[J]. J Cancer Res Clin Oncol, 2003； 129（1）∶17.
9.	Lau WY. Primary hepatocellular carcinoma [A]. In: Blumgart LH, Fong Y Eds. Disease of the Liver and Biliary Tract [M]. 3rd edn. London: WB Saunders Co. Ltd， 2000∶1423.
10.	Lau WY. Management of hepatocellular carcinoma [J]. J R Coll Surg Edinb, 2002； 47（1）∶389.
11.	Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres [J]. Int J Radiat Oncol Biol Phys, 1998； 40（3）∶583.
12.	Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia.
13.	Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma [J]. J Am Coll Surg, 2006; 202(1)∶155.
14.	Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablatire therapy for hepatocellular carcinoma: a review and lood into the future [J]. Ann Surg, 2003; 237(2)∶171.
15.	Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma [J]. Semin Oncol, 2001； 28（5）∶514.
16.	Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
17.	Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma.
18.	Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial [J]. Br J Cancer, 1989； 60（6）∶928.
19.	Lai CL, Lau JY, Wu PC, et al. Recombinant interferonalpha in inoperable hepatocellular carcinoma: a randomized controlled trial [J]. Hepatology, 1993； 17（3）∶389.
20.	Forbes A, Johnson PJ, Williams R. Recombinant human gammainterferon in primary hepatocellular carcinoma.
21.	The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma.
22.	Yoshida T, Okazaki N, Yoshino M, et al. Phase Ⅱ trial of high dose recombinant gammainterferon in advanced hepatocellular carcinoma.
23.	Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.
24.	Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alphainterferon therapy of advanced hepatocellular carcinoma [J]. Cancer， 1993； 71（7）∶2187.
25.	Bokemeyer C, Kynast B, Harstrick A, et al.No synergistic activity of epirubicin and interferonalpha 2b in the treatment of hepatocellular carcinoma [J]. Cancer Chemother Pharmacol,1995； 35（4）∶334.
26.	Patt YZ, Hassan MM, Lozano RD, et al. Phase Ⅱ trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa2b for treatment of hepatocellular carcinoma [J]. J Clin Oncol, 2003； 21（3）∶421.
27.	Feun LG, O’Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinomaA phase Ⅱ trial.
28.	Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma [J]. Clin Cancer Res, 1999； 5（7）∶1676.
29.	Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferonalpha, doxorubicin and 5fluorouracil chemotherapy [J]. Cancer, 2002； 94（2）∶421.
30.	Yin XY, Lu MD, Liang LJ, et al. Systemic chemoimmunotherapy for advancedstage hepatocellular carcinoma [J]. World J Gastroenterol, 2005； 11（16）∶2526.
31.	Yeo W, Mok TS, Zee B, et al. A randomized phase Ⅲ study of doxorubicin versus cisplatin/interferon alpha2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma [J]. J Natl Cancer Inst， 2005； 97（20）∶1532.
32.	Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma [J]. Ann Surg, 2004； 240（2）∶299.

1. [J]. Surgeon， 2005； 3（3）∶210.
2. [J]. Ann Surg， 2001； 233（2）∶236.
3. [J]. ChineseGerman J Clin Oncol， 2004； 3（3）∶130.
4. [J]. J R Soc Med, 1985； 78（10）∶826.
5. [J]. Cancer， 1990； 66（1）∶135.
6. [J]. Eur J Cancer, 1990； 26（4）∶545.
7. [J]. Hepatology, 2000； 31（1）∶54.
8. [J]. J Cancer Res Clin Oncol, 2003； 129（1）∶17.
9. Lau WY. Primary hepatocellular carcinoma [A]. In: Blumgart LH, Fong Y Eds. Disease of the Liver and Biliary Tract [M]. 3rd edn. London: WB Saunders Co. Ltd， 2000∶1423.
10. Lau WY. Management of hepatocellular carcinoma [J]. J R Coll Surg Edinb, 2002； 47（1）∶389.
11. Lau WY, Ho S, Leung TW, et al. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres [J]. Int J Radiat Oncol Biol Phys, 1998； 40（3）∶583.
12. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia.
13. Lau WY, Yu SC, Lai EC, et al. Transarterial chemoembolization for hepatocellular carcinoma [J]. J Am Coll Surg, 2006; 202(1)∶155.
14. Lau WY, Leung TW, Yu SC, et al. Percutaneous local ablatire therapy for hepatocellular carcinoma: a review and lood into the future [J]. Ann Surg, 2003; 237(2)∶171.
15. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma [J]. Semin Oncol, 2001； 28（5）∶514.
16. Lau WY, Leung TW, Lai BS, et al. Preoperative systemic chemoimmunotherapy and sequential resection for unresectable hepatocellular carcinoma.
17. Lau WY. Cure is possible with salvage surgery following downstaging of hepatocellular carcinoma.
18. Lai CL, Wu PC, Lok AS, et al. Recombinant alpha 2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trial [J]. Br J Cancer, 1989； 60（6）∶928.
19. Lai CL, Lau JY, Wu PC, et al. Recombinant interferonalpha in inoperable hepatocellular carcinoma: a randomized controlled trial [J]. Hepatology, 1993； 17（3）∶389.
20. Forbes A, Johnson PJ, Williams R. Recombinant human gammainterferon in primary hepatocellular carcinoma.
21. The Gastrointestinal Tumor Study Group. A prospective trial of recombinant human interferon alpha 2B in previously untreated patients with hepatocellular carcinoma.
22. Yoshida T, Okazaki N, Yoshino M, et al. Phase Ⅱ trial of high dose recombinant gammainterferon in advanced hepatocellular carcinoma.
23. Llovet JM, Sala M, Castells L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma.
24. Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alphainterferon therapy of advanced hepatocellular carcinoma [J]. Cancer， 1993； 71（7）∶2187.
25. Bokemeyer C, Kynast B, Harstrick A, et al.No synergistic activity of epirubicin and interferonalpha 2b in the treatment of hepatocellular carcinoma [J]. Cancer Chemother Pharmacol,1995； 35（4）∶334.
26. Patt YZ, Hassan MM, Lozano RD, et al. Phase Ⅱ trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa2b for treatment of hepatocellular carcinoma [J]. J Clin Oncol, 2003； 21（3）∶421.
27. Feun LG, O’Brien C, Molina E, et al. Recombinant leukocyte interferon, doxorubicin, and 5FUDR in patients with hepatocellular carcinomaA phase Ⅱ trial.
28. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma [J]. Clin Cancer Res, 1999； 5（7）∶1676.
29. Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferonalpha, doxorubicin and 5fluorouracil chemotherapy [J]. Cancer, 2002； 94（2）∶421.
30. Yin XY, Lu MD, Liang LJ, et al. Systemic chemoimmunotherapy for advancedstage hepatocellular carcinoma [J]. World J Gastroenterol, 2005； 11（16）∶2526.
31. Yeo W, Mok TS, Zee B, et al. A randomized phase Ⅲ study of doxorubicin versus cisplatin/interferon alpha2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma [J]. J Natl Cancer Inst， 2005； 97（20）∶1532.
32. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma [J]. Ann Surg, 2004； 240（2）∶299.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Systemic Chemo-Immunotherapy for Hepatocellular Carcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content